Navigation Links
Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
Date:10/17/2011

pected by 2014.

About Type 2 Diabetes

Type 2 diabetes is the most common form of diabetes and has reached epidemic proportions globally. The number of people worldwide living with diabetes (both type 1 and type 2) has reached 366 million, and the disease is responsible for 4.6 million deaths each year. Type 2 diabetes is a progressive and chronic condition and patients should work with a health care professional to manage and monitor their disease. In addition to diet and exercise, patients often need to take medications in order to help manage glucose control. The global health care expenditures to treat and prevent diabetes and its complications have reached $465 billion.

About TAK-875

TAK-875 is one of Takeda's investigational therapies for type 2 diabetes. TAK-875 is a selective agonist of GPR40, one of the G-protein-coupled receptors that are expressed in pancreatic islet cells. GPR40 agonists have a mechanism of action for type 2 diabetes different from that of sulfonylureas (such as glimepiride). They work by selectively improving glucose-dependent insulin secretion with a potential for reduced risk of hypoglycemia. Additional Phase 3 clinical trials for TAK-875 were initiated in Japan in September 2011.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.

About Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc.

Based in Deerfield, Ill., Takeda Pharmaceuticals North America,
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Takeda Completes Acquisition and Names New CEO of Nycomed
2. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
3. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
4. Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of ACTOS (pioglitazone HCl)
5. Takeda to Acquire Nycomed
6. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
7. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
8. Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takedas DEXILANT®
9. Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
10. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
11. Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Hearing health affects a man,s lifestyle, and if he wants ... engaged, he should address any hearing loss he may be ... Hearing Institute (BHI) is delivering to men around the ... which leads up to and includes Father,s Day. This year, ... 16. To help men address their hearing ...
(Date:5/23/2013)... 2013 More than half of women diagnosed ... chemotherapy and still have excellent outcomes. To educate women, ... the largest sources of online consumer information about breast ... page provide recently diagnosed women with information sources, to ... "We anticipate these innovative social media campaigns ...
(Date:5/23/2013)... Mass. , May 23, 2013  Hologic, ... HOLX ), a leading developer, manufacturer and supplier ... products, with an emphasis on serving the healthcare ... large-scale observational study in a U.S. clinical practice ... technology (breast tomosynthesis) with conventional 2D mammography alone ...
Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4
(Date:5/25/2013)... 25, 2013 By working diligently for ... the integration of the 2012 Lamborghini Aventador into their ... latest entrant in the list of vehicles lined by ... is all set to thrill automobile lovers in the ... and spectacular looks, the 2012 Lamborghini Aventador comes with ...
(Date:5/25/2013)... 25, 2013 Dr. Farooq Ashraf, founder ... in Dubai, has announced his practice’s adoption of The ... only FDA-cleared femtosecond laser proven with more than 10 ... precision of LASIK. , “We are happy to announce ... Laser at our Dubai LASIK practice,” Ashraf said Thursday. ...
(Date:5/25/2013)... IBISWorld estimates that revenue for the ... rate of 28.7% to $1.0 billion in the five years ... and 2008, no new cell therapy products were introduced, according ... during that period. In the years since, however, the Food ... factor contributed to the industry's fast growth during the five ...
(Date:5/25/2013)... 2013 Ayurveda is the traditional ... or wisdom of life". While a medical science, its scope ... of consciousness. Its fundamental philosophy is that disease is the ... It believes that in order to re-establish optimal health, we ... then adopt a life style which brings us back into ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 http://www.resource4thepeople.com/defectivedrugs/Actos-Bladder-Cancer-Lawsuit.html ... of a judge's overturning of a jury's award of ... the first trial* in the country over allegations that ... to court files. , The judge in the case ... to show his cancer was caused by the medication.** ...
Breaking Medicine News(10 mins):Health News:Rim Fitments Provider SizeItUp Launches The Database Integration For The 2012 Lamborghini Aventador 2Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Ayurveda Education Programs Offered by the California College of Ayurveda Include Panchakarma Certification, Practitioner Courses, and Body Therapy Classes 2Health News:Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases 2Health News:Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases 3Health News:Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases 4
... ANN ARBOR, Mich. The majority of parents feel ... for their child, according to researchers at the University ... new study published in the October issue of the ... they participate in decisions made about their hospitalized childs ...
... is one of four oral medications approved by ... the treatment of alcoholism. A recent large ... the National Institute of Alcoholism and Alcohol Abuse ... a modest but significant benefit but another FDA-approved ...
... Administering hydrogen sulfide (H 2 S) directly into the ... tissue and cell damage often seen in oxygen-starved organs, ... University of Alabama at Birmingham. , H 2 S ... an unwanted side effect of restoring blood flow swiftly ...
... talking about peripheral artery disease , , WEDNESDAY, Sept. ... spent decades tickling America,s funny bone and tugging ... health she,s working for now, crisscrossing the country ... and underdiagnosed cardiovascular threat called peripheral artery disease ...
... Clarient, Inc.,(Nasdaq: CLRT ), a premier technology ... today announced,that it is scheduled to make an investor ... 4:30 p.m. EDT on Wednesday, September,26, 2007. The conference ... York City,September 24-27. A live webcast of the ...
... Dairy Commission Supports Emission Limits, Buffer Zones to Protect ... ... Board of,Supervisors decided on Tuesday to defer action on a crucial proposal ... a,Planning Commission meeting-leaving unanswered the question of whether,dairy - - related pollution ...
Cached Medicine News:Health News:Parents' participation in medical decisions linked to self-efficacy 2Health News:Family history of alcoholism affects response to drug used to treat heavy drinking 2Health News:Severe heart attack damage limited by hydrogen sulfide 2Health News:'Cosby' Star Tackles a Silent Heart Threat 2Health News:'Cosby' Star Tackles a Silent Heart Threat 3Health News:'Cosby' Star Tackles a Silent Heart Threat 4Health News:Clarient to Present at the UBS 2007 Global Life Sciences Conference 2Health News:County Board Punts to Planning Commission On Clean-Air Issue 2
... C-Peptide is devoid of any biological activity ... the structural integrity of insulin. Although insulin ... in equimolar concentrations, fasting levels of C-Peptide ... insulin owing to the longer half-life of ...
Inquire...
Measles IgG ELISA test system is designed for the qualitative detection of IgG antibodies to Measles (Rubeola) virus in human serum, and is for in vitro diagnostic use....
... Zeus Scientific, Inc. Measles test ... qualitative and quantitative detection of ... by the indirect fluorescent antibody ... determine or confirm recent infection ...
Medicine Products: